CAMP4 Therapeutics reported a net loss of $33.5 million for Q2 2026, driven by a $20.9 million non-cash charge from the fair value change of derivative tranche liabilities associated with its September 2025 private placement. The company secured regulatory clearance in Australia and Argentina to initiate a first-in-human Phase 1/2 clinical trial for CMP-002 targeting SYNGAP-1 related disorders, with launch expected in Q4 2026. Additionally, CAMP4 raised $50.1 million from the second closing of its private placement, extending its cash runway through the end of 2028. Cash and equivalents stood at $86.4 million as of June 30, 2026. The company operates in the biopharmaceutical industry, developing regulatory RNA-targeting therapeutics to treat genetic diseases.

CAMP4 Therapeutics closed the second tranche of its private placement on August 3, 2026, generating approximately $50.1 million in gross proceeds. The company issued 10,756,498 shares of common stock at $1.53 per share and 21,925,368 pre-funded warrants at $1.5299 each. Management and directors also purchased an additional 39,306 shares at $1.65 per share. This closing was triggered by regulatory clearance from Australia’s Therapeutic Goods Administration for the Phase 1/2 trial of CMP-002. The total private placement raised approximately $100 million across two closings. CAMP4 Therapeutics is a clinical-stage biopharmaceutical company developing RNA-targeting therapeutics to treat genetic diseases.

CAMP4 Therapeutics Corporation received regulatory clearance from Australia's Therapeutic Goods Administration and local Human Research Ethics Committee to initiate a Phase 1/2 clinical trial of CMP-002 for SYNGAP1-related disorder. This regulatory milestone satisfies a condition in the company's September 2025 Securities Purchase Agreement, making the company eligible to receive up to $50.1 million in gross proceeds from a second closing of a private placement in exchange for up to 32,721,172 shares of common stock or pre-funded warrants. The second closing is expected to occur on or about August 3, 2026. CAMP4 Therapeutics is a clinical-stage biopharmaceutical company developing RNA-targeting therapeutics for genetic diseases.

At its June 10, 2026 annual meeting, stockholders approved an amendment to the 2024 Equity Incentive Plan to include outstanding pre-funded warrants in the evergreen provision calculation. Additionally, the Board approved a 2026 Inducement Plan allowing for the grant of up to 500,000 shares of common stock via various stock-based awards to new or rehired employees. The meeting also resulted in the election of Class II directors Steven Holtzman, Murray Stewart, and Richard Young, and the ratification of Ernst & Young LLP as the independent auditor. CAMP4 Therapeutics Corporation is a biotechnology company focused on developing therapeutics.